Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | IA Mayer, CL Arteaga, R Nanda, KD Miller, K Jhaveri, AM Brufsky, H Rugo, DA Yardley, LT Vahdat, S Sadeghi, MW Audeh, L Rolfe, J Litten, A Knox, M Raponi, C Tankersley, J Isaacson, K Wride, DE Morganstern, C Vogel, RM Connolly, WJ Gradishar, R Patel etl al | ||||||||||||
Title | A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC) | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/77/4_Supplement/P6-11-03.short | ||||||||||||
Abstract Text | Cancer Res 2017;77(4 Suppl):Abstract nr P6-11-03 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|